GBA1 and Parkinson disease: Our finding of significantly reduced paraxanthine at baseline in PD-LRRK2 and PD-GBA1 cohorts therefore aligns with these metabolomic signatures and suggests that diminished paraxanthine exposure—or accelerated clearance—may associate with elevated risk or earlier phenoconversion in these genotypes.